127 related articles for article (PubMed ID: 34217697)
1. Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.
van Winden LJ; Lanfermeijer M; Heijboer AC; van Tellingen O; Bergman AM; van der Poel HG; Jonker N; van Rossum HH
Clin Chim Acta; 2021 Oct; 521():70-75. PubMed ID: 34217697
[TBL] [Abstract][Full Text] [Related]
2. Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.
van Winden LJ; Lentjes EGWM; Demir AY; Huijgen HJ; Bergman AM; van der Poel HG; van Rossum HH
Clin Chem Lab Med; 2022 Sep; 60(10):1661-1668. PubMed ID: 35918785
[TBL] [Abstract][Full Text] [Related]
3. Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.
van Winden LJ; Lanfermeijer M; Dezentje V; Bergman AM; van der Poel HG; van Rossum HH
Clin Chim Acta; 2023 Jan; 539():34-40. PubMed ID: 36460134
[TBL] [Abstract][Full Text] [Related]
4. LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.
van Nuland M; Venekamp N; Wouters WME; van Rossum HH; Rosing H; Beijnen JH
J Pharm Biomed Anal; 2019 Jun; 170():161-168. PubMed ID: 30925273
[TBL] [Abstract][Full Text] [Related]
5. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
[TBL] [Abstract][Full Text] [Related]
6. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
[TBL] [Abstract][Full Text] [Related]
7. High-throughput analysis of testosterone in serum samples by on-line solid phase extraction liquid chromatography-tandem mass spectrometry.
Savolainen K; Kiimamaa R; Halonen T
Clin Chem Lab Med; 2011 Nov; 49(11):1845-8. PubMed ID: 21756165
[TBL] [Abstract][Full Text] [Related]
8. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
9. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
[TBL] [Abstract][Full Text] [Related]
10. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
11. Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT).
Tiwari R; Lajkosz K; Berjaoui M; Qaoud Y; Kenk M; Woffendin C; Caron P; Guillemette C; Fleshner N
Urol Oncol; 2022 May; 40(5):193.e15-193.e20. PubMed ID: 35437219
[TBL] [Abstract][Full Text] [Related]
12. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
[TBL] [Abstract][Full Text] [Related]
13. Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies?
Kalogera E; Pistos C; Provatopoulou X; Athanaselis S; Spiliopoulou C; Gounaris A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():24-34. PubMed ID: 24140653
[TBL] [Abstract][Full Text] [Related]
14. Discordance between testosterone measurement methods in castrated prostate cancer patients.
Rouleau M; Lemire F; Déry M; Thériault B; Dubois G; Fradet Y; Toren P; Guillemette C; Lacombe L; Klotz L; Saad F; Guérette D; Pouliot F
Endocr Connect; 2019 Feb; 8(2):132-140. PubMed ID: 30673630
[TBL] [Abstract][Full Text] [Related]
15. Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
Pouliot F; Rouleau M; Neveu B; Toren P; Morin F; Vélot L; Ding K; Caron P; Lacombe L; Lévesque É; Klotz L; Guillemette C
J Urol; 2020 May; 203(5):940-948. PubMed ID: 31845837
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Measurement of Serum Chemical Castration Agents and Testosterone Levels Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Ko DH; Lee K; Jeon SH; Song SH; Yun YM; Chun S; Kim HS; Kim JY; In MK; Song J
J Anal Toxicol; 2016 May; 40(4):294-303. PubMed ID: 26989223
[TBL] [Abstract][Full Text] [Related]
17. Biological variation of serum neopterin concentrations in apparently healthy individuals.
Dülgeroğlu Y; Ercan M
Clin Chem Lab Med; 2024 Mar; 62(4):706-712. PubMed ID: 37882748
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurement of testosterone, androstenedione and dehydroepiandrosterone (DHEA) in serum and plasma using Isotope-Dilution 2-Dimension Ultra High Performance Liquid-Chromatography Tandem Mass Spectrometry (ID-LC-MS/MS).
Büttler RM; Martens F; Kushnir MM; Ackermans MT; Blankenstein MA; Heijboer AC
Clin Chim Acta; 2015 Jan; 438():157-9. PubMed ID: 25172041
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry.
Shiraishi S; Lee PW; Leung A; Goh VH; Swerdloff RS; Wang C
Clin Chem; 2008 Nov; 54(11):1855-63. PubMed ID: 18801940
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration.
Comas I; Ferrer R; Planas J; Celma A; Regis L; Morote J
Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):86-93. PubMed ID: 28259362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
